Get the Stockscreener App
143.00
0.52%
0.74
Pre-market:
143.20
0.20
+0.14%
Biogen Inc stock is traded at $143.00, with a volume of 1.01M.
It is up +0.52% in the last 24 hours and down -1.29% over the past month.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
See More
Previous Close:
$142.26
Open:
$142.1
24h Volume:
1.01M
Relative Volume:
0.63
Market Cap:
$20.97B
Revenue:
$9.61B
Net Income/Loss:
$1.53B
P/E Ratio:
13.68
EPS:
10.453
Net Cash Flow:
$1.85B
1W Performance:
-2.44%
1M Performance:
-1.29%
6M Performance:
+20.56%
1Y Performance:
-24.56%
1-Day Range:
$141.67
$144.32
1-Week Range:
$141.67
$147.56
52-Week Range:
$110.03
$191.19
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
143.00 | 20.86B | 9.61B | 1.53B | 1.85B | 10.45 |
|
LLY
Lilly Eli Co
|
802.83 | 734.54B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
193.22 | 462.69B | 92.15B | 25.12B | 18.18B | 10.36 |
|
ABBV
Abbvie Inc
|
229.57 | 400.78B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
131.43 | 253.15B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
84.79 | 209.61B | 63.43B | 16.42B | 14.72B | 6.4861 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-25 | Initiated | Jefferies | Buy |
| Jul-21-25 | Resumed | Truist | Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-04-25 | Downgrade | Argus | Buy → Hold |
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Nordea Investment Management AB Purchases 6,811 Shares of Biogen Inc. $BIIB - MarketBeat
J.L. Bainbridge Exits Most of Biogen Stake as Biotech Stock Eyes Turnaround - The Motley Fool
Is a relief rally coming for Biogen Inc. holdersTrade Volume Report & Smart Allocation Stock Reports - newser.com
Is Biogen Inc. stock a top momentum playLong Setup & Technical Pattern Alert System - newser.com
Is Biogen Inc. stock a safe buy before earningsWeekly Gains Report & Reliable Volume Spike Trade Alerts - newser.com
Sector ETF performance correlation with Biogen Inc.Market Rally & Reliable Breakout Forecasts - newser.com
New York State Teachers Retirement System Has $13.90 Million Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Ritholtz Wealth Management Buys Shares of 6,076 Biogen Inc. $BIIB - MarketBeat
Will LEQEMBI IQLIK’s At-Home Launch Redefine Biogen’s (BIIB) Alzheimer’s Treatment Story? - simplywall.st
Is it time to cut losses on Biogen Inc.2025 Buyback Activity & Fast Gain Swing Alerts - newser.com
Is Biogen Inc. stock a buy before product launchesQuarterly Growth Report & Smart Swing Trading Alerts - nchmf.gov.vn
Applied Finance Capital Management LLC Invests $465,000 in Biogen Inc. $BIIB - MarketBeat
TD Asset Management Inc Has $17.96 Million Holdings in Biogen Inc. $BIIB - MarketBeat
Yousif Capital Management LLC Has $2.48 Million Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Is Biogen Inc. stock a defensive play in 20252025 Historical Comparison & AI Forecast Swing Trade Picks - nchmf.gov.vn
How Biogen Inc. stock compares to market leadersTreasury Yields & Reliable Trade Execution Plans - nchmf.gov.vn
Using portfolio simulators with Biogen Inc. includedQuarterly Trade Review & Stock Market Timing Techniques - newser.com
Biogen (BIIB) Gains Momentum with Patient Opportunity Equity Str - GuruFocus
Key metrics from Biogen Inc.’s quarterly dataPortfolio Gains Report & Daily Growth Stock Investment Tips - newser.com
Wedbush Has Optimistic Outlook of Biogen Q1 Earnings - MarketBeat
Allianz Asset Management GmbH Has $66.19 Million Position in Biogen Inc. $BIIB - MarketBeat
Cwm LLC Acquires 6,639 Shares of Biogen Inc. $BIIB - MarketBeat
Callan Family Office LLC Purchases Shares of 2,454 Biogen Inc. $BIIB - MarketBeat
Biogen Inc. Stock Falls by 3.65% - Idéal Investisseur
Is Biogen Now an Opportunity After Recent 25% Share Price Decline? - simplywall.st
Alzheimer's Disease Market: Epidemiology, Therapies, - openPR.com
Wedbush Comments on Biogen's FY2025 Earnings (NASDAQ:BIIB) - MarketBeat
Hourglass Capital LLC Purchases Shares of 17,970 Biogen Inc. $BIIB - MarketBeat
Looking at the Changing Narrative for Biogen After Recent Pipeline and Market Developments - Yahoo Finance
Generali Asset Management SPA SGR Purchases 2,518 Shares of Biogen Inc. $BIIB - MarketBeat
NorthRock Partners LLC Invests $391,000 in Biogen Inc. $BIIB - MarketBeat
US Bancorp DE Sells 8,837 Shares of Biogen Inc. $BIIB - MarketBeat
3 Reasons BIIB is Risky and 1 Stock to Buy Instead - The Globe and Mail
Biogen Inc. stock outperforms competitors on strong trading day - MSN
(BIIB) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Biogen Inc (IDP.SG) stock price, news, quote and history - Yahoo
When is the best time to exit Biogen Inc.July 2025 Review & Capital Protection Trading Alerts - newser.com
Wedbush Forecasts Biogen's Q3 Earnings (NASDAQ:BIIB) - MarketBeat
Autoinjectors Market 2025: Industry Drug Delivery, Smart - openPR.com
Vanguard Personalized Indexing Management LLC Has $4.39 Million Position in Biogen Inc. $BIIB - MarketBeat
Is Biogen Inc. (IDP) stock a buy on weaknessPortfolio Update Report & Real-Time Chart Pattern Alerts - newser.com
Biogen (BIIB) to Report Q3 Earnings Amid IPR&D Expense Impact - GuruFocus
Biogen (BIIB) Valuation: Assessing Market Discount After Recent Signs of Financial Stabilization - simplywall.st
Biogen sees negative impact on Q3 EPS from IPR&D expense - Seeking Alpha
Biogen expects $2 million research and development expense in Q3 2025 - Investing.com India
Biogen expects estimated charge to impact net income per diluted share for Q3 by $-0.01 - MarketScreener
CD40 Targeting Therapy Clinical Trials Anti CD40 Antibody Therapy Market Opportunity Assessment Insight - GlobeNewswire Inc.
Biogen (NASDAQ:BIIB) Price Target Raised to $135.00 - MarketBeat
Wedbush Raises Price Target on Biogen to $135 From $129, Keeps Neutral Rating - MarketScreener
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" - ACN Newswire
Aberdeen Group plc Purchases 9,942 Shares of Biogen Inc. $BIIB - MarketBeat
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.20%
3.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):